Abstract: The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Abstract: A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user’s behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user’s behavioral model using the first algorithm, providing a customized user’s behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user’s behavioral model.

Abstract: A method involves detecting in a sample an autoantibody binding specifically to one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2. An autoantibody binds specifically to one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2. A diagnostically useful carrier with a solid phase with an immobilized polypeptide contains one or more from Gluk1, Gluk2, Gluk3, Gluk4 and Gluk5, preferably Gluk2 or a variant thereof. The autoantibody can be used for diagnosing a neurological autoimmune disease or a cancer.

Abstract: The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

Abstract: The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

Abstract: The method comprising acquiring and analyzing by computer means image information of video sequences of two or more dimensions obtained from contrast-enhanced signals, for example ultrasound, coherence tomography, fluorescence images, or Magnetic Resonance Imaging, of a body part or tissue, for example of an organ, of a living subject; detecting events from said information of video sequences; selecting a Region of Interest of said body part or tissue; computing a first graph representative of a local vascular network of said image information of video sequences in which the edges of the graph are estimated by the temporal relationship among spatially remote signals of said image information of video sequences within a set of video sequences; and using said graph for assessment of vascular networks.

Abstract: The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections.

Abstract: The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

Abstract: The method comprising acquiring and analysing by computer means image information of video sequences of two or more dimensions obtained from contrast-enhanced signals, for example ultrasound, coherence tomography, fluorescence images, or Magnetic Resonance Imaging, of a body part or tissue, for example of an organ, of a living subject; detecting events from said information of video sequences; selecting a Region of Interest of said body part or tissue; computing a first graph representative of a local vascular network of said image information of video sequences in which the edges of the graph are estimated by the temporal relationship among spatially remote signals of said image information of video sequences within a set of video sequences; and using said graph for assessment of vascular networks.

Abstract: The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the ? or ? chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease.

Abstract: The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections.

Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.

Abstract: Equipment for infrared vision of anatomical structures applicable to assist the physicians in endoscopic, fetoscopic or laparoscopic operations and methods for signal processing to enhance said vision, comprising two units that work together: a multimodal or multispectral imaging unit, constituted by a device comprising an endoscope or fetoscope or laparoscope, and additional optical systems to acquire multimodal images of the interior of the patient's body; and an image processing unit, to which said images are transferred, comprising processing devices with a navigation interface which process said images and display the patient's enhanced anatomical map image and the endoscope location, equipped with hardware and software that apply at least five different vision-enhancing methods, namely normalization, segmentation, tracking, mapping and fusion.

Abstract: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.

Abstract: The invention relates to the use of an antibody or a fragment thereof, specific against substance P, for the manufacture of a medicament for therapeutic treatment of a cancer expressing NK1 receptor and/or a ErbB receptor family member (i.e. the epidermal growth factor receptors family), by direct administration to a mammal, including a human. The administration of an antibody against substance P to a panel of breast cancer cell lines, inhibits HER2 activation and expression, causing a downregulation of different genes involved in cell cycle progression, like cyclin D1, cyclin E, cdk4 and cdk2. A decrease in proliferation and an arrest in G1 phase of cell cycle are observed. On the other hand, the antibody causes an induction of apoptosis.